Correlation Between 23Andme Holding and Allogene Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both 23Andme Holding and Allogene Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 23Andme Holding and Allogene Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between 23Andme Holding Co and Allogene Therapeutics, you can compare the effects of market volatilities on 23Andme Holding and Allogene Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 23Andme Holding with a short position of Allogene Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of 23Andme Holding and Allogene Therapeutics.

Diversification Opportunities for 23Andme Holding and Allogene Therapeutics

0.63
  Correlation Coefficient

Poor diversification

The 3 months correlation between 23Andme and Allogene is 0.63. Overlapping area represents the amount of risk that can be diversified away by holding 23Andme Holding Co and Allogene Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Allogene Therapeutics and 23Andme Holding is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on 23Andme Holding Co are associated (or correlated) with Allogene Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Allogene Therapeutics has no effect on the direction of 23Andme Holding i.e., 23Andme Holding and Allogene Therapeutics go up and down completely randomly.

Pair Corralation between 23Andme Holding and Allogene Therapeutics

Allowing for the 90-day total investment horizon 23Andme Holding Co is expected to generate 0.92 times more return on investment than Allogene Therapeutics. However, 23Andme Holding Co is 1.09 times less risky than Allogene Therapeutics. It trades about -0.09 of its potential returns per unit of risk. Allogene Therapeutics is currently generating about -0.17 per unit of risk. If you would invest  361.00  in 23Andme Holding Co on October 3, 2024 and sell it today you would lose (36.00) from holding 23Andme Holding Co or give up 9.97% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

23Andme Holding Co  vs.  Allogene Therapeutics

 Performance 
       Timeline  
23Andme Holding 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days 23Andme Holding Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in February 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Allogene Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Allogene Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

23Andme Holding and Allogene Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with 23Andme Holding and Allogene Therapeutics

The main advantage of trading using opposite 23Andme Holding and Allogene Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 23Andme Holding position performs unexpectedly, Allogene Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will offset losses from the drop in Allogene Therapeutics' long position.
The idea behind 23Andme Holding Co and Allogene Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Complementary Tools

AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance